Efficacy of Buspirone Augmentation of Escitalopram in Patients with Major Depressive Disorder with and without Atypical Features: A Randomized, 8 Week, Multicenter, Open-Label Clinical Trial

키워드

참고문헌 (55)

1. Spijker J, "Functional disability and depression in the general population. Results from the Netherlands Mental Health Survey and Incidence Study (NEMESIS)", Acta Psychiatr Scand, 110, pp.208~214 (2004)
2. Russo M, "Measuring cognitive function in MDD : emerging assessment tools", Depress Anxiety, 32, pp.262~269 (2015)
3. Zuckerman H, "Recognition and treatment of cognitive dysfunction in major depressive disorder", Front Psychiatry, 9, pp.655~ (2018)
4. Rush AJ, "Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps : a STAR*D report", Am J Psychiatry, 163, pp.1905~1917 (2006)
5. Nelson JC, "Augmentation treatment in major depressive disorder : focus on aripiprazole", Neuropsychiatr Dis Treat, 4, pp.937~948 (2008)
6. Apter JT, "Buspirone : future directions", J Clin Psychopharmacol, 19, pp.86~93 (1999)
7. Lechin F, "Effects of buspirone on plasma neurotransmitters in healthy subjects", J Neural Transm(Vienna), 105, pp.561~573 (1998)
8. Fabre LF, "Buspirone in the management of major depression : a placebo-controlled comparison", J Clin Psychiatry, 51(Suppl), pp.55~61 (1990)
9. Heiser JF, "Serotonin 5-HT 1a receptor agonists as antidepressants", Cns Drugs, 10, pp.343~353 (1998)
10. McAllister-Williams RH, "Somatodendritic 5-hydroxytryptamine1A(5-HT1A)autoreceptor function in major depression as assessed using the shift in electroencephalographic frequency spectrum with buspirone", Psychol Med, 44, pp.767~777 (2014)
11. Depoortere R, "F15599, a preferential post-synaptic 5-HT1A receptor agonist : activity in models of cognition in comparison with reference 5-HT1A receptor agonists", Eur Neuropsychopharmacol, 20, pp.641~654 (2010)
12. Micheau J, "Stimulation of 5-HT1A receptors by systemic or medial septum injection induces anxiogenic-like effects and facilitates acquisition of a spatial discrimination task in mice", Prog Neuropsychopharmacol Biol Psychiatry, 23, pp.1113~1133 (1999)
13. Givens BS, "Cholinergic and GABAergic modulation of medial septal area : effect on working memory", Behav Neurosci, 104, pp.849~855 (1990)
14. Haleem DJ, "Dose related effects of buspirone on pain, learning", memory and food intake, 2018, pp.99, 182~190
15. Sumiyoshi T, "Enhancement of cognitive performance in schizophrenia by addition of tandospirone to neuroleptic treatment", Am J Psychiatry, 158, pp.1722~1725 (2001)
16. Sumiyoshi T, "Effect of buspirone, a serotonin1A partial agonist, on cognitive function in schizophrenia : a randomized, double-blind, placebo-controlled study", Schizophr Res, 95, pp.158~168 (2007)
17. Gili M, "Clinical patterns and treatment outcome in patients with melancholic, atypical and non-melancholic depressions", PLoS One, 7, pp.e48200~ (2012)
18. Singh T, "Atypical depression", Psychiatry(Edgmont), 3, pp.33~39 (2006)
19. Anisman H, "Endocrine and cytokine correlates of major depression and dysthymia with typical or atypical features", Mol Psychiatry, 4, pp.182~188 (1999)
20. Juruena MF, "Atypical depression and non-atypical depression : is HPA axis function a biomarker? A systematic review", J Affect Disord, 233, pp.45~67 (2018)
21. Pizzagalli DA, "Functional but not structural subgenual prefrontal cortex abnormalities in melancholia", Mol Psychiatry, 9, pp.325~ (2004)
22. Exner C, "Impaired implicit learning and reduced presupplementary motor cortex size in early-onset major depression with melancholic features", J Affect Disord, 119, pp.156~162 (2009)
23. Austin MP, "Cognitive function in depression: a distinct pattern of frontal impairment in melancholia?", Psychol Med, 29, pp.73~85 (1999)
24. Brown WA, "Treatment response in melancholia", Acta Psychiatr Scand Suppl, pp.125~129 (2007)
25. Hamilton M, "A rating scale for depression", J Neurol Neurosurg Psychiatry, 23, pp.56~62 (1960)
26. Stewart JW, "Atypical depression. A valid clinical entity?", Psychiatr Clin North Am, 16, pp.479~495 (1993)
27. Hamilton M, "The assessment of anxiety states by rating", Br J Med Psychol, 32, pp.50~55 (1959)
28. Beck AT, "An inventory for measuring depression", Arch Gen Psychiatry, 4, pp.561~571 (1961)
29. Beck AT, "An inventory for measuring clinical anxiety : psychometric properties", J Consult Clin Psychol, 56, pp.893~897 (1988)
30. Guy W, "ECDEU Assessment manual for psychopharmacology", US Department of Health, and Welfare, 534~537 (1976)
31. Treynor W, "Rumination reconsidered : A psychometric analysis", Cogn Ther Res, 27, pp.247~259 (2003)
32. Wechsler D, "Wechsler Adult Intelligence Scale (WAIS–IV), 22", pp.498~ (2008), NCS Pearson
33. Morris JC, "The Consortium to Establish a Registry for Alzheimer’s Disease(CERAD). Part I. Clinical and neuropsychological assessment of Alzheimer’s disease", Neurology, 39, pp.1159~1165 (1989)
34. Bowie CR, "Administration and interpretation of the Trail Making Test", Nat Protoc, 1, pp.2277~2281 (2006)
35. Fitzmaurice GM, "Applied Longitudinal Analysis" (2012), John Wiley & Sons
36. Appelberg BG, "Patients with severe depression may benefit from buspirone augmentation of selective serotonin reuptake inhibitors:results from a placebo-controlled, randomized, double-blind, placebo wash-in study", J Clin Psychiatry, 62, pp.448~452 (2001)
37. Landen M, "A randomized, double-blind, placebo-controlled trial of buspirone in combination with an SSRI in patients with treatment-refractory depression", J Clin Psychiatry, 59, pp.664~668 (1998)
38. Onder E, "Faster response in depressive patients treated with fluoxetine alone than in combination with buspirone", J Affect Disord, 76, pp.223~227 (2003)
39. Wagner S, "A meta-analysis of executive dysfunctions in unipolar major depressive disorder without psychotic symptoms and their changes during antidepressant treatment", Acta Psychiatr Scand, 125, pp.281~292 (2012)
40. Keefe RS, "Cognitive effects of pharmacotherapy for major depressive disorder : a systematic review", J Clin Psychiatry, 75, pp.864~876 (2014)
41. Rosenblat JD, "The cognitive effects of antidepressants in major depressive disorder : a systematic review and meta-analysis of randomized clinical trials", Int J Neuropsychopharmacol, 19, pp.pyv082~ (2015)
42. Murrough JW, "Cognitive dysfunction in depression: neurocircuitry and new therapeutic strategies", Neurobiol Learn Mem, 96, pp.553~563 (2011)
43. Hoffman BM, "Exercise fails to improve neurocognition in depressed middle-aged and older adults", Med Sci Sports Exerc, 40, pp.1344~1352 (2008)
44. Robinson M, "Acute and long-term treatment of late-life major depressive disorder : duloxetine versus placebo", Am J Geriatr Psychiatry, 22, pp.34~45 (2014)
45. Rocca P, "Citalopram versus sertraline in late-life nonmajor clinically significant depression : a 1-year follow-up clinical trial", J Clin Psychiatry, 66, pp.360~369 (2005)
46. Bondareff W, "Comparison of sertraline and nortriptyline in the treatment of major depressive disorder in late life", Am J Psychiatry, 157, pp.729~736 (2000)
47. Levkovitz Y, "The SSRIs drug Fluoxetine, but not the noradrenergic tricyclic drug Desipramine, improves memory performance during acute major depression", Brain Res Bull, 58, pp.345~350 (2002)
48. Finkel SI, "Comparative efficacy of sertraline vs. fluoxetine in patients age 70 or over with major depression", Am J Geriatr Psychiatry, 7, pp.221~227 (1999)
49. McIntyre RS, "A randomized, double-blind, placebo-controlled study of vortioxetine on cognitive function in depressed adults", Int J Neuropsychopharmacol, 17, pp.1557~1567 (2014)
50. Lamers F, "Evidence for a differential role of HPA-axis function, inflammation and metabolic syndrome in melancholic versus atypical depression", Mol Psychiatry, 18, pp.692~699 (2013)
51. Savitz J, "5-HT(1A)receptor function in major depressive disorder", Prog Neurobiol, 88, pp.17~31 (2009)
52. Schmidt HD, "The role of neurotrophic factors in adult hippocampal neurogenesis, antidepressant treatments and animal models of depressive-like behavior", Behav Pharmacol, 18, pp.391~418 (2007)
53. Olsen AS, "Traumatic brain injury-induced cognitive and histological deficits are attenuated by delayed and chronic treatment with the 5-HT1A-receptor agonist buspirone", J Neurotrauma, 29, pp.1898~1907 (2012)
54. Monaco CM, "A combined therapeutic regimen of buspirone and environmental enrichment is more efficacious than either alone in enhancing spatial learning in brain-injured pediatric rats", J Neurotrauma, 31, pp.1934~1941 (2014)
55. Lojko D, "Atypical depression : current perspectives", Neuropsychiatr Dis Treat, 13, pp.2447~2456 (2017)